<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210617051606N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-13</date_registration>
      <primary_sponsor>Razi University</primary_sponsor>
      <public_title>The effect of exercise training and Camelina oil consumption on type 2 diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of 8 weeks of combined home-based exercise and Camelina oil consumption on insulin resistance, lipid profile, quality of life and some psychological indices in women with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58573</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, permuted block randomization via the www.randomization.com website will be used. To do so, first, a unique number will be allocated to each subject as the identifier code and, a 48-digit sequence (equal to sample size) will be created. Then, treatment labels including 1) exercise + Camelina group; 2) Exercise group; 3) Camelina group, and 4) control group will be entered in the relevant section on the website. After defining the treatment groups and to avoid potential problems associated with equal block sizes, permuted block randomization with differents block sizes will be applied. In this case, by knowing the sample size, the block sizes will be unequal and a multiple of the number of treatment groups (for example, block sizes of 2, 4, 6, or 8). The website has the ability to randomly specify the sequence of blocks with different sizes. In the final step and upon performing the 'Generate Plan' on the website, all subjects will be randomly assigned to blocks of different sizes that already have a random sequence. Finally, the group (treatment) of each subject will be specified by the use of the identifier code and checking out the blocks.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group (Exercise + Camelina): this group performs combined home-based aerobic and bodyweight resistance training 3 times a week for 8 weeks. The intensity of aerobic and resistance training will be controlled by the use of a 6-20 Borg scale. In the first week, the training intensity will be 11 and, in week 8, the intensity will be 13 on the Borg scale. The aerobic training is in category A according to American College of Sports Medicine (ACSM) guidelines that require minimum skill and physical fitness. The resistance training includes Squat, Lunges, and Push-up by the use of body weight. This group also consumes 27 grams of Camelina oil per day with meals for 8 weeks. This oil is transparent yellow in color and has no unusual taste and smell. Camelina oil has a standard document proved by Iran National Standards Organization. Intervention 2: Intervention group 2 (Exercise): this group performs combined home-based aerobic and bodyweight resistance training 3 times a week for 8 weeks. The intensity of aerobic and resistance training will be controlled by the use of a 6-20 Borg scale. In the first week, the training intensity will be 11 and, in week 8, the intensity will be 13 on the Borg scale. The aerobic training is in category A according to American College of Sports Medicine (ACSM) guidelines that require minimum skill and physical fitness. The resistance training includes Squat, Lunges, and Push-up by the use of body weight. Intervention 3: Intervention group 3 (Camelina): This group consumes 27 grams of Camelina oil per day with meals for 8 weeks. This oil is transparent yellow in color and has no unusual taste and smell. Camelina oil has a standard document proved by Iran National Standards Organization. Intervention 4: Control group: this group has the the normal life during the study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data are shared after the de-identification of the participants

When:
3 months after publication

To whom:
All individuals upon formal request

Conditions:
Data sharing requests are accepted for any purposes

Where to obtain:
To obtain any data/document, please send an e-mail to Ehsan Amiri, a faculty member at Razi University, through the following e-mail address: e.amiri@razi.ac.ir

How to obtain:
Upon formal request, mentioning due reasons, and providing full personality details, data will be sent after 72 h via e-mail

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsan Amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 73, Faculty of Sport Sciences, Razi University, Tagh-e-Bostan, University St., Kermanshah, Iran</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3845 8428</telephone>
        <email>e.amiri@razi.ac.ir</email>
        <affiliation>Razi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ehsan Amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Room 73. Faculty of Sport Sciences, Razi University, University St, Taq-e-Bostan, Kermanshah, Iran</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3427 7609</telephone>
        <email>e.amiri@razi.ac.ir</email>
        <affiliation>Razi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Not participation in regular exercise training over the last 6 months
Having type 2 diabetes confirmed by specialist
Fasting blood glucose of equal or more than 126 milligrams in deciliter to 400 milligrams in deciliter
No insulin injection
Getting the certification of no prohibition of participating in exercise training program from a specialist</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Acute or chronic inflammatory diseases
Heart diseases
Pregnancy
Alcohol and other kinds of drug addiction
Musculoskeletal disorder
Refusal to give informed consent</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group (Exercise + Camelina): this group performs combined home-based aerobic and bodyweight resistance training 3 times a week for 8 weeks. The intensity of aerobic and resistance training will be controlled by the use of a 6-20 Borg scale. In the first week, the training intensity will be 11 and, in week 8, the intensity will be 13 on the Borg scale. The aerobic training is in category A according to American College of Sports Medicine (ACSM) guidelines that require minimum skill and physical fitness. The resistance training includes Squat, Lunges, and Push-up by the use of body weight. This group also consumes 27 grams of Camelina oil per day with meals for 8 weeks. This oil is transparent yellow in color and has no unusual taste and smell. Camelina oil has a standard document proved by Iran National Standards Organization.</i_keyword>
      <i_keyword>Intervention group 2 (Exercise): this group performs combined home-based aerobic and bodyweight resistance training 3 times a week for 8 weeks. The intensity of aerobic and resistance training will be controlled by the use of a 6-20 Borg scale. In the first week, the training intensity will be 11 and, in week 8, the intensity will be 13 on the Borg scale. The aerobic training is in category A according to American College of Sports Medicine (ACSM) guidelines that require minimum skill and physical fitness. The resistance training includes Squat, Lunges, and Push-up by the use of body weight.</i_keyword>
      <i_keyword>Intervention group 3 (Camelina): This group consumes 27 grams of Camelina oil per day with meals for 8 weeks. This oil is transparent yellow in color and has no unusual taste and smell. Camelina oil has a standard document proved by Iran National Standards Organization.</i_keyword>
      <i_keyword>Control group: this group has the the normal life during the study</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Changes in insulin resistance. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By blood sample and Hemostatic Model Assessment for Insulin Resistance (HOMA-IR). In this case, fasting blood insulin and glucose are measured and then, they will be put in the HOMA-IR formula.</prim_outcome>
      <prim_outcome>Changes in fasting blood glucose. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By blood sample in fasting condition.</prim_outcome>
      <prim_outcome>Changes in lipid profile. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By blood sample in fasting condition.</prim_outcome>
      <prim_outcome>Change in quality of life. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: World health organization standard quality of life questionnaire (short version).</prim_outcome>
      <prim_outcome>Change in depression severity. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: Hamilton Depression Rating Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Change in physical self-concept. Timepoint: Before intervention and after 8 weeks of intervention. Method of measurement: Physical self-concept questionnaire.</sec_outcome>
      <sec_outcome>Change in the quality of sleep. Timepoint: Before intervention and after 8 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index.</sec_outcome>
      <sec_outcome>Change in anxiety. Timepoint: Before intervention and after 8 weeks of intervention. Method of measurement: Beck Anxiety Inventory.</sec_outcome>
      <sec_outcome>Change in self-esteem. Timepoint: Before intervention and after 8 weeks of intervention. Method of measurement: Rosenberg’s Self-Esteem Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Razi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-23</approval_date>
        <contact_name>Research Ethics Committees of Kermanshah Razi University</contact_name>
        <contact_address>Deputy of Research and Technology, Razi University, University Str, Taq-e-bostan, Kermanshah, Iran Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
